South Korean aesthetic device maker Agnes Medical has been selected for the Ministry of SMEs and Startups' 'Global Strong 1000+' program, a government initiative supporting high-potential export SMEs. The designation signals growing international recognition for its dermatological devices, including the AGNES and AGNES Ultra systems, and may interest overseas distributors seeking certified, regulatory-cleared aesthetic equipment.
Government endorsement and support
The 'Global Strong 1000+' program, run by the Ministry of SMEs and Startups, identifies promising export-oriented small and medium enterprises and provides marketing, financial, and export assistance. Selected companies receive bundled support from multiple government agencies to accelerate overseas market entry and scale exports. For Agnes Medical, this endorsement adds a layer of official credibility that can reassure international buyers evaluating new device suppliers.
Company background and leadership
Agnes Medical was founded in 2018 by Chief Technology Officer Ahn Kun-young, a dermatologist who graduated from Chung-Ang University Medical School. Ahn previously founded Goonsesang Dermatology Clinic in 1998 and Goonsesang Cosmetic in 2000, which built the popular dermocosmetic brand Dr.G. Goonsesang Cosmetic recorded sales of approximately 230.3 billion KRW (about USD 175 million). Ahn now focuses on growing Agnes Medical into a global aesthetic device company.
Key products and global regulatory progress
The company's flagship device, AGNES, treats syringoma and acne. Its newer model, AGNES Ultra, has been launched in the United States and other markets. Another product, DoubleTite, delivers energy simultaneously to the papillary and reticular dermis, attracting attention in the beauty industry. These devices have obtained regulatory approvals in the United States, Europe, Brazil, Japan, and other major markets, demonstrating a growing global footprint.
What buyers should watch
For overseas distributors and clinic buyers, Agnes Medical's inclusion in the Global Strong 1000+ program suggests the company is likely to receive enhanced government support for export activities, potentially improving supply reliability and market entry assistance. The company's devices already hold approvals in key markets, reducing regulatory risk for new partners. Buyers evaluating aesthetic devices for acne, syringoma, or skin tightening applications may want to monitor Agnes Medical's product pipeline and distribution expansion plans.
Company statement
"Being selected for the Global Strong 1000+ program is a meaningful achievement that recognizes our technology and growth potential," an Agnes Medical representative said. "We plan to accelerate our overseas market expansion through continued R&D and global network development."
Source: Read the original report | Published: June 16, 2026